financetom
Business
financetom
/
Business
/
BRIEF-Alkane And Mandalay Announce Closing Of Merger
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Alkane And Mandalay Announce Closing Of Merger
Aug 5, 2025 5:09 AM

Mandalay Resources Corp ( MNDJF ):

* ALKANE AND MANDALAY ANNOUNCE CLOSING OF MERGER

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bitcoin hovers near all-time high
Bitcoin hovers near all-time high
Oct 6, 2025
NEW YORK (Reuters) -Bitcoin hovered near its record high on Monday as the world's largest cryptocurrency by market value continued to benefit from strong demand from investors. The rally in bitcoin since the start of the year has been underpinned by flows from institutional investors, friendlier policies of the administration of U.S. President Donald Trump, and increasing connection with global...
-- Sun Life Brief: Appointing Tom Murphy as President, Sun Life Asset Management
-- Sun Life Brief: Appointing Tom Murphy as President, Sun Life Asset Management
Oct 6, 2025
11:03 AM EDT, 10/06/2025 (MT Newswires) -- Price: 84.89, Change: +0.72, Percent Change: +0.86 ...
Looking At Newmont's Recent Unusual Options Activity
Looking At Newmont's Recent Unusual Options Activity
Oct 6, 2025
Investors with a lot of money to spend have taken a bullish stance on Newmont ( NEM ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big...
Why Is Abivax Stock Trading Higher On Monday?
Why Is Abivax Stock Trading Higher On Monday?
Oct 6, 2025
Abivax SA ( ABVX ) shared additional clinical data on Monday for obefazimod at the United European Gastroenterology (UEG) Meeting. These data, from the Phase 3 ABTECT 8-Week Induction Trials investigating obefazimod for moderate-to-severely active ulcerative colitis, highlight additional efficacy endpoint data at week eight for patients with and without prior advanced therapy inadequate response (AT-IR). A total of 1,272 patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved